The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•21 April 2026•

1 min read

Addex Therapeutics Reports Positive Preclinical Data for Chronic Cough Candidate

Key Facts

1Addex's GABAB PAM candidate demonstrated robust anti-tussive activity in a non-human primate (NHP) chronic cough model.

2The company focuses on developing small molecule allosteric modulators for neurological disorders.

Addex Therapeutics has announced successful preclinical results for its GABAB PAM candidate, demonstrating robust anti-tussive activity in non-human primate models for chronic cough. The company specializes in the development of small molecule allosteric modulators designed to treat various neurological disorders. These positive findings represent a significant milestone in validating the GABAB PAM platform for respiratory-related indications. By achieving efficacy in primate models, Addex underscores the potential versatility of its pipeline beyond traditional neurology. While the candidate remains in the early stages of development, the data provides a strong foundation for future clinical trials. This advancement is expected to bolster investor confidence in the company's long-term therapeutic strategy and innovative approach to drug discovery.